EGFR and central nervous system cancer: Analysis of molecular diagnostic testing data from 71 glioma patients revealed that the incidence of EGFR mutations in gliomas was 30.99% (22/71), with EGFRvIII mutation being the most common form, accounting for approximately 21.13% (15/71) of all gliomas, followed by EGFR amplification, accounting for approximately 16.90% (12/71) of all gliomas, and finally EGFR point mutation, accounting for approximately 11.27% (8/71) of all gliomas (Fig. S1A, B).